Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Minerva Neurosciences faces FDA challenges with roluperidone in Q4

Minerva Neurosciences' Q4 2022 earnings call highlighted challenges with FDA interactions for roluperidone, alongside financial updates. Despite hurdles, the company expressed confidence in its data package and the potential of roluperidone to meet medical needs. Ongoing FDA dialogue remains critical for addressing regulatory concerns and advancing the schizophrenia treatment.

Minerva Neurosciences advances NDA filing for roluperidone, faces regulatory challenges

Minerva Neurosciences showcased progress in drug development and financial stability while facing challenges in regulatory processes and financial uncertainties. The company's strategic focus on unique drug profiles and milestone achievements presents opportunities for growth and market success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

Company to Request Pre-NDA Meeting with U.S. Food and Drug Administration Company to Request Pre-NDA Meeting with U.S. Food and Drug Administration

Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia

Investors need to pay close attention to Minerva Neurosciences (NERV) stock based on the movements in the options market lately.

Implied Volatility Surging for Minerva Neurosciences (NERV) Stock Options

Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q2 2021 Results - Earnings Call Transcript

Minerva Neurosciences (NERV) delivered earnings and revenue surprises of -47.06% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Minerva Neurosciences (NERV) Reports Q2 Loss, Lags Revenue Estimates

WALTHAM, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended June 30, 2021.

Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates

Minerva Neurosciences (NERV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Minerva Neurosciences (NERV) to Report a Decline in Earnings: What to Look Out for

Management to host conference call Management to host conference call

Minerva Neurosciences to Report Second Quarter 2021 Financial Results and Business Updates on August 2, 2021

WALTHAM, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the virtual JMP Securities Life Sciences Conference on June 16, 2021 at 10:00 a.m. Eastern Time.

Minerva Neurosciences to Present at JMP Securities Life Sciences Conference

WALTHAM, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the Jefferies Virtual Healthcare Conference on June 2, 2021 at 11:00 a.m. Eastern Time.

Minerva Neurosciences to Present at Jefferies Virtual Healthcare Conference

Minerva Neurosciences (NERV) has moved higher as of late, but there could definitely be trouble on the horizon for this company

Minerva Neurosciences (NERV) Enters Overbought Territory

Do Options Traders Know Something About Minerva Neurosciences (NERV) Stock We Don't?

CYREN

OPKO Health

Waitr Holdings Inc

Looking for penny stocks to buy during a market correction? Check these 4 out for your watchlist The post Best Penny Stocks to Buy During a Market Correction?

Best Penny Stocks to Buy During a Market Correction? Check These 4 Out

Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q1 2021 Results - Earnings Call Transcript

Evofem Biosciences Inc

Novan

Obalon Therapeutics

Biotech penny stocks are heating up right now; here's 4 to watch The post Best Biotech Penny Stocks to Buy Under $5? 4 To Check Out in May appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Biotech Penny Stocks to Buy Under $5? 4 To Check Out in May

Minerva (NERV) is developing its lead pipeline candidate, roluperidone, in patients with negative symptoms of schizophrenia. Positive data from an extension of previously completed late-stage study boosts investors' sentiment.

Minerva (NERV) Soars on Promising Schizophrenia Study Data

Top-line results from the open-label extension of phase 3 monotherapy trial of roluperidone for the treatment of negative symptoms of schizophrenia show continuous improvement in negative symptoms, improved functional ability, favorable safety profile and limited number of psychotic relapses over one year

Minerva Neurosciences Reports First Quarter 2021 Financial Results and Business Updates

The stock price of Minerva Neurosciences Inc (NASDAQ: NERV) increased by over 25% pre-market. This is why it happened.

NERV Stock: Over 25% Increase Pre-Market Explanation

WALTHAM, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced results from the 40-week open-label extension (OLE) of its phase 3 trial of roluperidone for the treatment of negative symptoms (NS) of schizophrenia. The OLE followed the 12-week double-blind, placebo-controlled portion of this trial. During the OLE, both investigators and patients were blinded to the roluperidone dose received (see “About the trial” below).

Minerva Neurosciences Announces the Results of the Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia Following the Completion of the 40-Week Open-Label Extension

Minerva Neurosciences to Report First Quarter 2021 Financial Results and Business Updates on May 12, 2021

Is the Options Market Predicting a Spike in Minerva Neurosciences (NERV) Stock?

Minerva Neurosciences, Inc.'s (NERV) CEO Remy Luthringer on Q4 2020 Results - Earnings Call Transcript

Phase 3 open-label extension completed on schedule in patients with negative symptoms of schizophrenia and data will be available in H1 2021

Minerva Neurosciences Reports Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates

LOS ANGELES, Feb. 8, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Minerva Neurosciences, Inc. ("Minerva" or "the Company") (NASDAQ: NERV) for violations of §§10(b) and 20(a) of the...

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Minerva Neurosciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - February 8, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) ("Minerva Neurosciences") between May 15, 2017 and November 30, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Massachusetts. To get more...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Minerva Neurosciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 8, 2021 - NERV

New York, New York--(Newsfile Corp. - February 8, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 2017 and November 30, 2020, inclusive (the "Class Period"), of the important February 8, 2021 lead plaintiff deadline.SO WHAT: If you purchased Minerva securities during the Class Period you may be entitled to compensation without payment of any out of pocket...

NERV DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Minerva Neurosciences, Inc. Investors to Secure Counsel Before Important Monday Deadline - NERV

News for Minerva Neurosciences Stock (NERV)